Skip to main content
SpringerLink
Log in

Predictive In Vivo Models for Oncology

  • Chapter
New Approaches to Drug Discovery

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 232))

Abstract

Experimental oncology research and preclinical drug development both substantially require specific, clinically relevant in vitro and in vivo tumor models. The increasing knowledge about the heterogeneity of cancer requested a substantial restructuring of the test systems for the different stages of development. To be able to cope with the complexity of the disease, larger panels of patient-derived tumor models have to be implemented and extensively characterized. Together with individual genetically engineered tumor models and supported by core functions for expression profiling and data analysis, an integrated discovery process has been generated for predictive and personalized drug development.

Improved “humanized” mouse models should help to overcome current limitations given by xenogeneic barrier between humans and mice. Establishment of a functional human immune system and a corresponding human microenvironment in laboratory animals will strongly support further research.

Drug discovery, systems biology, and translational research are moving closer together to address all the new hallmarks of cancer, increase the success rate of drug development, and increase the predictive value of preclinical models.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alcantar-Orozco EM, Gornall H, Baldan V, Hawkins RE, Gilham DE (2013) Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer. Hum Gene Ther Methods 24(5):310–320

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10):1626–1634

    Article  CAS  PubMed  Google Scholar 

  • Amendt C, Staub E, Friese-Hamim M, Störkel S, Stroh C (2014) Association of EGFR expression level and cetuximab activity in patient-derived xenograft models of human non-small cell lung cancer. Clin Cancer Res 20(17):4478–4487

    Article  CAS  PubMed  Google Scholar 

  • Angevin E, Glukhova L, Pavon C, Chassevent A, Terrier-Lacombe MJ, Goguel AF, Bougaran J, Ardouin P, Court BH, Perrin JL, Vallancien G, Triebel F, Escudier B (1999) Human renal cell carcinoma xenografts in SCID mice: tumorigenicity correlates with a poor clinical prognosis. Lab Invest 79:879–888

    CAS  PubMed  Google Scholar 

  • Bankert RB, Egilmez NK, Hess S (2001) Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol 22:386–393

    Article  CAS  PubMed  Google Scholar 

  • Bankert RB, Balu-Iyer SV, Odunsi K, Shultz LD, Kelleher RJ, Barnas JL (2011) Humanized mouse models of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS One 6:e24420

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Becker M, Nitsche A, Neumann C, Aumann J, Junghahn I, Fichtner I (2002) Sensitive PCR method for the detection and real-time quantification of human cells in xenotransplantation systems. Br J Cancer 87(11):1328–1335

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Becker M, Sommer A, Krätzschmar JR, Seidel H, Pohlenz HD, Fichtner I (2004) Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Ther 4:151–168

    Google Scholar 

  • Behrens D, Hallas C, Anders D, Hoffmann J, Fichtner I (2014) In vivo models of pancreatic cancer for translational medicine. Eur J Cancer 50(Supplement 5):S1–S247

    Google Scholar 

  • Bosma MJ, Carroll AM (1991) The SCID mouse mutant: definition, characterization, and potential uses. Annu Rev Immunol 9:323–335

    Article  CAS  PubMed  Google Scholar 

  • Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T, Kleindienst P, Wimberger P, Kimmig R, Fichtner I, Kufer P, Hofmeister R, da Silva AJ, Baeuerle PA (2006) MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 43:1129–1143

    Article  CAS  PubMed  Google Scholar 

  • Cao S, Durrani FA, Tóth K, Rustum YM (2014) Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models. Br J Cancer 110(7):1733–1743

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Carter TC, Dunn LC, Falconer DS (1952) Standardized nomenclature for inbred strains of mice: prepared by the committee on standardized nomenclature for inbred strains of mice. Cancer Res 12:602–613

    Google Scholar 

  • Chiarugi P, Paoli P, Cirri P (2014) Tumor microenvironment and metabolism in prostate cancer. Semin Oncol 41(2):267–280

    Article  CAS  PubMed  Google Scholar 

  • Cook RS, Jacobsen KM, Wofford AM, DeRyckere D, Stanford J, Prieto AL, Redente E, Sandahl M, Hunter DM, Strunk KE, Graham DK, Earp HS 3rd (2013) MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis. J Clin Invest 123(8):3231–3242

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cree IA, Glaysher S, Harvey AL (2010) Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr Opin Pharmacol 10(4):375–379

    Article  CAS  PubMed  Google Scholar 

  • daChuna A, Michelin MA, Murta EF (2014) Pattern of response of dendritic cells in the tumor microenvironment and breast cancer. World J Clin Oncol 5(3):495–502

    Article  Google Scholar 

  • Decaudin D (2011) Primary human tumor xenografted models (“tumorgrafts”) for good management of patients with cancer. Anticancer Drugs 22:827–841

    Article  CAS  PubMed  Google Scholar 

  • Dechantsreiter MA, Planker E, Matha B, Lohof E, Holzemann G, Jonczyk A (1999) N-methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 42:3033–3040

    Article  CAS  PubMed  Google Scholar 

  • Dreier T, Baeuerle PA, Fichtner I, Grün M, Schlereth B, Lorenczewski G, Kufer P, Lutterbüse R, Riethmüller G, Gjorstrup P, Bargou RC (2003) T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol 170:4397–4402

    Article  CAS  PubMed  Google Scholar 

  • Duechler M, Peczek L, Szubert M, Suzin J (2014) Influence of hypoxia inducible factors on the immune microenvironment in ovarian cancer. Anticancer Res 34(6):2811–2819

    CAS  PubMed  Google Scholar 

  • Fang H, DeClerk YA (2013) Targeting the tumor microenvironment: from understanding pathways to effective clinical trails. Cancer Res 73(16):4965–4977

    Article  CAS  PubMed  Google Scholar 

  • Fichtner I, Becker M, Zeisig R, Sommer A (2004) In vivo models for endocrine-dependent breast carcinomas: special considerations of clinical relevance. Eur J Cancer 40:845–851

    Article  CAS  PubMed  Google Scholar 

  • Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J (2008) Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 14(20):6456–6468

    Article  CAS  PubMed  Google Scholar 

  • Fu S, Wang J, Sun W, Xu Y, Zhou X, Cheng W (2014) Preclinical humanized mouse model with ectopic ovarian tissues. Exp Ther Med 8(3):742–746

    PubMed  PubMed Central  Google Scholar 

  • Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, Bowman LC, Ma MK, Hoffer FA, Meyer WH, Pappo AS, Walter AW, Houghton PJ (1999) Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 17:1815–1824

    CAS  PubMed  Google Scholar 

  • Futakuchi M, Singh RK (2013) Animal model for mammary tumor growth in the bone microenvironment. Breast Cancer 20(3):195–203

    Article  PubMed  Google Scholar 

  • Garber K (2009) From human to mouse and back: ‘tumorgraft’ models surge in popularity. J Natl Cancer Inst 101:6–8

    Article  PubMed  Google Scholar 

  • Garralda E, Paz K, López-Casas PP, Jones S, Katz A, Kann LM, López-Rios F, Sarno F, Al-Shahrour F, Vasquez D, Bruckheimer E, Angiuoli SV, Calles A, Diaz LA, Velculescu VE, Valencia A, Sidransky D, Hidalgo M (2014) Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment. Clin Cancer Res 20(9):2476–2484

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C (2011) Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res 17:5793–5800

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Goubran HA, Kotb RR, Stakiw J, Emara ME, Burnouf T (2014) Regulation of tumor growth and metastasis: the role of tumor microenvironment. Cancer Growth Metastasis 7:9–18

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Haddad TC, Yee D (2008) Of mice and (wo)men: is this any way to test a new drug? J Clin Oncol 26:830–832

    Article  CAS  PubMed  Google Scholar 

  • Hammer S, Sommer A, Fichtner I, Becker M, Rolff J, Merk J, Klar U, Hoffmann J (2010) Comparative profiling of the novel epothilone, Sagopilone, in xenografts derived from primary non-small cell lung cancer. Clin Cancer Res 16:1452–1465

    Article  CAS  PubMed  Google Scholar 

  • Henderson D, Ogilvie LA, Hoyle N, Keilholz U, Lange B, Lehrach H, OncoTrack Consortium (2014) Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack. Biotechnol J 9(9)

    Google Scholar 

  • Hersey P, Sosman J, O’Day S, Richards J, Bedikian A, Gonzalez R (2010) A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or − dacarbazine in patients with stage IV metastatic melanoma. Cancer 116:1526–1534

    Article  CAS  PubMed  Google Scholar 

  • Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, Roman-Roman S, Seoane J, Trusolino L, Villanueva A (2014) Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 4(9):998–1013

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hoffmann J, Fichtner I, Lemm M, Lienau P, Hess-Stumpp H, Rotgeri A, Hofmann B, Klar U (2009) Sagopilone crosses the blood–brain barrier in vivo to inhibit brain tumor growth and metastases. Neuro Oncol 11(2):158–166

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hoffmann J, Orthmann A, Hoffmann A, Reiner R, Fichtner I (2014) Establishment and validation of models for metastasis developed from patient xenogragrafts (PDX). In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, 2014 Apr 5–9. AACR, San Diego. Abstract 4953

    Google Scholar 

  • Hylander BL, Punt N, Tang H, Hillmann J, Vaughan M, Bshara W (2013) Origin of the vasculature supporting growth of primary patient tumor xenografts. J Transl Med 11:110

    Article  PubMed  PubMed Central  Google Scholar 

  • Kelloff GJ, Sigman CC (2012) Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov 11:201–214

    Article  CAS  PubMed  Google Scholar 

  • Lee H (2014) Genetically engineered mouse models for drug development and preclinical trials. Biomol Ther (Seoul) 22(4):267–274

    Article  CAS  Google Scholar 

  • Lee TK, Na KS, Kim J, Jeong HJ (2014) Establishment of animal models with orthotopic hepatocellular carcinoma. Nucl Med Mol Imaging 48(3):173–179

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66(8):3992–3995

    Article  PubMed  Google Scholar 

  • Malaney P, Nicosia SV, Davé V (2014) One mouse, one patient paradigm: new avatars of personalized cancer therapy. Cancer Lett 344(1):1–12

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • McCullough DJ, Nguyen LM, Siemann DW, Behnke BJ (2013) Effects of exercise training on tumor hypoxia and vascular function in the rodent preclinical orthotopic prostate cancer model. J Appl Physiol 115(12):1846–1854

    Article  PubMed  PubMed Central  Google Scholar 

  • Monsma DJ, Monks NR, Cherba DM, Dylewski D, Eugster E, Jahn H, Srikanth S, Scott SB, Richardson PJ, Everts RE, Ishkin A, Nikolsky Y, Resau JH, Sigler R, Nickoloff BJ, Webb CP (2012) Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue. J Transl Med 10:125

    Article  PubMed  PubMed Central  Google Scholar 

  • Morton CL, Houghton PJ (2007) Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc 2(2):247–250

    Article  CAS  PubMed  Google Scholar 

  • Nevins JR, Huang ES, Dressman H, Pittman J, Huang AT, West M (2003) Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction. Hum Mol Genet 12(Spec No 2):R153–R157

    Article  CAS  PubMed  Google Scholar 

  • Nwabo Kamdje AH, Muller JM, Lukong KE (2014) Signaling pathways in breast cancer: therapeutic targeting of the microenvironment. Cell Signal. doi:10.1016/j.cellsig.2014.07.034

    Google Scholar 

  • O’Day S, Pavlick A, Loquai C, Lawson D, Gutzmer R, Richards J (2011) A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer 105:346–352

    Article  PubMed  PubMed Central  Google Scholar 

  • Park SI, Kim SJ, McCauley LK, Gallick GE (2010) Pre-clinical mouse models of human prostate cancer and their utility in drug discovery. Curr Protoc Pharmacol Chapter 14:Unit 14.15. doi:10.1002/0471141755.ph1415s5

    Google Scholar 

  • Paulsson J, Ehnman M, Ostman A (2014) PDGF receptors in tumor biology: prognostic and predictive potential. Future Oncol 10(9):1695–1708

    Article  CAS  PubMed  Google Scholar 

  • Pechanska P, Becker M, Mayr T (2013) Mutation status of KRAS, BRAF, PIK3CA and expression level of AREG and EREG identify responders to cetuximab in a large panel of patient derived colorectal carcinoma xenografts of all four UICC stages. J Cancer Ther. doi:10.4236/jct.2013

    Google Scholar 

  • Perez-Soler R, Kemp B, Wu QP, Mao L, Gomez J, Zeleniuch-Jacquotte A, Yee H, Lee JS, Jagirdar J, Ling YH (2006) Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 6:4932–4938

    Google Scholar 

  • Peterson JK, Houghton PJ (2004) Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 40:837–844

    Article  CAS  PubMed  Google Scholar 

  • Rappaport A, Johnson L (2014) Genetically engineered knock-in and conditional knock-in mouse models of cancer. Cold Spring Harb Protoc 2:2014(9)

    Google Scholar 

  • Reisfeld RA (2013) The tumor microenvironment: a target for combination therapy of breast cancer. Crit Rev Oncog 18(1–2):115–133

    Article  PubMed  Google Scholar 

  • Rivera M, Keil M, Boehnke K, Lange M, Schumacher D, Schäfer R, Regenbrecht CRA, Henderson D, Keilholz U, Kuehn A, El-Heliebi A, Hohensee T, Haybäck J, Reinhard C, Velasco JA, Lehrach H, Garin-Chesa P, Beran G, Hoffmann J (2014) Generation of drug response data from 57 new patient-derived colon cancer xenografts and 3D cell cultures for systematic correlation with tumor biology within the OncoTrack* project. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, 2014 Apr 5–9. AACR, San Diego, CA. Abstract 2978

    Google Scholar 

  • Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty SV, Teichmann LL, Saito Y, Marches F, Halene S, Palucka AK, Manz MG, Flavell RA (2014) Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol 32(4):364–372

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rossi ML, Rehman AA, Gondi CS (2014) Therapeutic options for the management of pancreatic cancer. World J Gastroenterol 20(32):11142–11159

    Article  PubMed  PubMed Central  Google Scholar 

  • Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C (2006) An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 12:4652–4661

    Article  CAS  PubMed  Google Scholar 

  • Schlereth B, Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, da Silva A, Kufer P, Lutterbuese R, Junghahn I, Kasimir-Bauer S, Wimberger P, Kimmig R, Baeuerle PA (2005) Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res 65:2882–2889

    Article  CAS  PubMed  Google Scholar 

  • Schmieder R, Hoffmann J, Becker M, Bhargava A, Müller T, Kahmann N, Ellinghaus P, Adams R, Rosenthal A, Thierauch KH, Scholz A, Wilhelm SM, Zopf D (2014) Regorafenib (BAY 73–4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer. Int J Cancer 135(6):1487–1496

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Scott CL, Becker MA, Haluska P, Samimi G (2013) Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Front Oncol 3(295):1–8

    Google Scholar 

  • Sebastiani V, Ricci F, Rubio-Viqueira B, Kulesza P, Yeo CJ, Hidalgo M (2006) Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res 12:2492–2497

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sharpless NE, Depinho RA (2006) The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5:741–754

    Article  CAS  PubMed  Google Scholar 

  • Shull JD (2007) The rat oncogenome: comparative genetics and genomics of rat models of mammary carcinogenesis. Breast Dis 28:69–86

    CAS  PubMed  Google Scholar 

  • Siolas D, Hannon GJ (2013) Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res 73:5315–5319

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Slamon D, Pegram M (2001) Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28(1 Suppl 3):13–19

    Article  CAS  PubMed  Google Scholar 

  • Smith HW, Muller WJ (2013) Transgenic mouse models – a seminal breakthrough in oncogene research. Cold Spring Harb Protoc 12:1099–1108

    Google Scholar 

  • Sommer A, Hoffmann J, Lichtner RB, Schneider MR, Parczyk K (2003) Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines. J Steroid Biochem Mol Biol 85(1):33–47

    Article  CAS  PubMed  Google Scholar 

  • Stromnes IM, Schmitt TM, Chapuis AG, Hingorani SR, Greenberg PD (2014) Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunol Rev 257(1):145–164

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Strube A, Hoffmann J, Stepina E, Hauff P, Klar U, Käkönen SM (2009) Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption. Clin Cancer Res 15(11):3751–3759

    Article  CAS  PubMed  Google Scholar 

  • Thibaudeau L, Taubenberger AV, Holzapfel BM, Quent VM, Fuehrmann T, Hesami P, Brown TD, Dalton PD, Power CA, Hollier BG, Hutmacher DW (2014) A tissue-engineered humanized xenograft model of human breast cancer metastasis to bone. Dis Model Mech 7(2):299–309

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tran PH, Tran TT, Lee BJ (2014) Biodistribution and pharmacokinetics in rats and antitumor effect in various types of tumor-bearing mice of novel self-assembled gelatin-oleic acid nanoparticles containing paclitaxel. J Biomed Nanotechnol 10(1):154–165

    Article  CAS  PubMed  Google Scholar 

  • Tschida BR, Largaespada DA, Keng VW (2014) Mouse models of cancer: sleeping beauty transposons for insertional mutagenesis screens and reverse genetic studies. Semin Cell Dev Biol 27:86–95

    Article  CAS  PubMed  Google Scholar 

  • Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703

    Article  Google Scholar 

  • Wang T, Liu G, Wang R (2014) The intercellular metabolic interplay between tumor and immune cells. Front Immunol 5:358

    PubMed  PubMed Central  Google Scholar 

  • Wege AK, Schmidt M, Ueberham E, Ponnath M, Ortmann O, Brockhoff G, Lehmann J (2014) Co-transplantation of human hematopoietic stem cells and human breast cancer cells in NSG mice: a novel approach to generate tumor cell specific human antibodies. MAbs 6(4):968–977

    Article  PubMed  PubMed Central  Google Scholar 

  • Wenzel J, Zeisig R, Haider W, Habedank S, Fichtner I (2010) Inhibition of pulmonary metastasis in a human MT3 breast cancer xenograft model by dual liposomes preventing intravasal fibrin clot formation. Breast Cancer Res Treat 121(1):13–22

    Article  CAS  PubMed  Google Scholar 

  • Zhang L, Cao DY, Wang J, Xiang B, Dun JN, Fang Y, Xue GQ (2013) PEG-coated irinotecan cationic liposomes improve the therapeutic efficacy of breast cancer in animals. Eur Rev Med Pharmacol Sci 17(24):3347–3361

    CAS  PubMed  Google Scholar 

  • Zhou Q, Facciponte J, Jin M, Shen Q, Lin Q (2014) Humanized NOD-SCID IL2rg−/− mice as a preclinical model for cancer research and its potential use for individualized cancer therapies. Cancer Lett 344(1):13–19

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. EPO – Experimental Pharmacology and Oncology – GmbH, Robert-Roessle-Str. 10, 13125, Berlin, Germany

    Diana Behrens, Jana Rolff & Jens Hoffmann

Authors
  1. Diana Behrens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jana Rolff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jens Hoffmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Diana Behrens .

Editor information

Editors and Affiliations

  1. Drug Discovery-Cross Indication Platform, Bayer Pharma AG, Wuppertal, Germany

    Ulrich Nielsch

  2. Drug Discovery-Cross Indication Platform, Bayer Pharma AG, Berlin, Berlin, Germany

    Ulrike Fuhrmann

  3. Drug Discovery-Global External Innovation & Alliances, Bayer Pharma AG, Berlin, Berlin, Germany

    Stefan Jaroch

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Behrens, D., Rolff, J., Hoffmann, J. (2015). Predictive In Vivo Models for Oncology. In: Nielsch, U., Fuhrmann, U., Jaroch, S. (eds) New Approaches to Drug Discovery. Handbook of Experimental Pharmacology, vol 232. Springer, Cham. https://doi.org/10.1007/164_2015_29

Download citation

Publish with us

Policies and ethics

Search

Navigation